MyGLP-1 Ingredients & Drug Interactions
What is this page for?
First and foremost: checking MyGLP-1 against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
MyGLP-1 is a dietary supplement by Purity Products with 3 active ingredients. Its ingredients are commonly taken for blood sugar support in type 2 diabetes, weight loss and appetite control, insulin sensitivity.Based on those ingredients, 178 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Chromium. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against MyGLP-1 by Purity Products
Ask about any prescription or over-the-counter medication and we check it for interactions with MyGLP-1 by Purity Products — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of MyGLP-1 by Purity Products
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Full disclosure
MyGLP-1 contains three active ingredients. Chromium is a mineral that plays a role in blood sugar control and is used to address chromium deficiency and support glucose metabolism.
The other two actives are eriocitrin, slendacor, and eriomin — a blend ingredient whose components aren't broken down separately in our data. The capsule also contains inactive ingredients (hypromellose, rice flour, magnesium stearate, and sodium copper chlorophyllin) that help hold it together and deliver the actives.
Does it work?
Not established
Chromium is likely effective for chromium deficiency and possibly effective for type 2 diabetes. For prediabetes and impaired glucose tolerance, the evidence rates as possibly ineffective, and data does not support use for schizophrenia or high blood pressure.
We don't hold effectiveness ratings for eriocitrin, slendacor, or eriomin in our data, so we can't speak to whether they work for the product's intended purpose.
How safe is it?
Well-documented data
Chromium is generally well tolerated at typical supplement doses. The most common side effects are gastrointestinal irritation, headaches, insomnia, irritability, and mood changes.
Skin rashes and urticaria have been reported as well. Rare serious effects — kidney and liver damage, muscle breakdown (rhabdomyolysis), and low platelet counts (thrombocytopenia) — have been documented, usually with high doses taken long-term.
For pregnancy, chromium from food or prenatal vitamins is likely safe, but additional supplement doses should be avoided unless your doctor recommends it. The same caution applies to breastfeeding.
We hold no safety data for eriocitrin, slendacor, or eriomin during pregnancy or breastfeeding.
Meds to double-check
Moderate interaction found
Before taking MyGLP-1, double-check with us if you take antidiabetes drugs or insulin (major risk of low blood sugar), levothyroxine for your thyroid (moderate — reduced absorption), NSAIDs or aspirin (minor — may raise chromium levels). No interactions are documented for the other two active ingredients, but we have no data to check them against.
The bottom line
Scorecard at a glanceFully disclosed formula with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.
This product is worth considering if you have low chromium levels or want targeted support for blood sugar control — but only after talking to your doctor, especially if you take diabetes medications, thyroid hormone, or pain relievers. Your pharmacist can help you space out doses and watch for low blood sugar.
Check your exact medications with the tool on this page before you start.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 1 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Apr 24, 2025.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about MyGLP-1, straight from the product label.
| Brand | Purity Products |
|---|---|
| Net contents | 60 Vegetarian Capsule(s) |
| Market status | On market |
| Date entered into DSLD | Apr 24, 2025 |
| DSLD ID | 331214 |
| Product type | Other Combinations |
| Supplement form | Capsule |
| Dietary claims / uses | All Other, Structure/Function |
| Intended target group(s) | Adult (18 - 50 Years) |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for MyGLP-1 by Purity Products, sourced from the NIH Dietary Supplement Label Database.
Supplement Facts
| Ingredient | Amount | % DV |
|---|---|---|
| Chromium | 200 mcg | 571% |
| Eriocitrin | 140 mg | -- |
| Slendacor | 900 mg | -- |
| Eriomin | 200 mg | -- |
Other ingredients: Hypromellose, Rice Flour, Magnesium Stearate, Sodium Copper Chlorophyllin
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation
My GLP-1 support ProClinical Lose an average of 12 lbs with SLENDACOR Supports reduction in hip & waist size
Does not contain GLP-1
FDA Statement of Identity
Dietary Supplement
Suggested/Recommended/Usage/Directions
Suggested use: As a dietary supplement, take 2 capsules daily. For daily use.
Brand IP Statement(s)
Chromax, including the Chromax logo, is a registered trademark of Nutrition 21, LLC. Chromax is patent protected. SLENDACOR is a reigstered trademark of PLT Health Solutions-Laila Nutraceuticals LLC. U.S. Patent # 8,541,383 and patents pending. Eriomin is a registered trademark of Ingredients by Nature, LLC.
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
MyGLP-1 by Purity Products label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in MyGLP-1 by Purity Products
These are the 3 active ingredients this product is made of. Select any to open its full monograph.
Serving size2 Vegetarian Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.
Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.
Chromium
Interacts with178 drugs
Chromium is an essential trace mineral involved in how the body handles sugar and fat. Some studies suggest it may modestly help blood sugar control i...
Chromium monograph & interactionsSlendacor
Eriomin
- › Eriocitrin
Other (inactive) ingredients: Hypromellose, Rice Flour, Magnesium Stearate, Sodium Copper Chlorophyllin. These complete the product’s ingredient list but are not active constituents.
MyGLP-1 by Purity Products Drug Interactions
HelloPharmacist Interaction Report
MyGLP-1 by Purity Products contains chromium, which interacts with several medication types.
The most serious concern is with antidiabetes drugs and insulin — chromium may add to their blood sugar-lowering effect and increase your risk of low blood sugar (hypoglycemia). If you take diabetes medication, your doctor may need to adjust your dose.
Read the full breakdown — every affected drug type, severity by severity
Chromium also interacts with levothyroxine (the thyroid hormone in Synthroid and generics). Taking them together can reduce how much thyroid hormone your body absorbs — clinical research shows a 17% drop in blood levels.
Space them at least several hours apart, or talk to your doctor about timing. Additionally, NSAIDs and aspirin may increase how much chromium your body absorbs, though the clinical significance of this is unclear.
We could not check the interaction data for eriocitrin and slendacor — two of the three active ingredients. Eriomin is listed as a blend; we hold no separate monograph for it.
Altogether, these interactions span 178 individual medications. Run your exact prescriptions through the checker on this page before you start.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against MyGLP-1?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in MyGLP-1 interact with 178 drugs. Click any drug to see the details.
1 of the 3 ingredients in MyGLP-1 interact with drugs. Each result below shows which ingredient is responsible. Chromium
AcarboseGlucobay, Prandase, Precose
How Acarbose interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Acarbose interactionAcetohexamideDymelor
How Acetohexamide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Acetohexamide interactionAlbiglutideTanzeum
How Albiglutide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Albiglutide interactionAlogliptinNesina
How Alogliptin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Alogliptin interactionAlogliptin, MetforminKazano
How Alogliptin, Metformin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Alogliptin, Metformin interactionAlogliptin, PioglitazoneOseni
How Alogliptin, Pioglitazone interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Alogliptin, Pioglitazone interactionAntidiabetes, Dipeptidyl Peptidase-4 (dpp-iv) InhibitorGlyxambi
How Antidiabetes, Dipeptidyl Peptidase-4 (dpp-iv) Inhibitor interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Antidiabetes, Dipeptidyl Peptidase-4 (dpp-iv) Inhibitor interactionCanagliflozinInvokana
How Canagliflozin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Canagliflozin interactionCanagliflozin, MetforminInvokamet
How Canagliflozin, Metformin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Canagliflozin, Metformin interactionCanagliflozin, Metformin HydrochlorideInvokamet XR
How Canagliflozin, Metformin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Canagliflozin, Metformin Hydrochloride interactionChlorpropamideChlorpropam, Diabinese
How Chlorpropamide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Chlorpropamide interactionDapagliflozinFarxiga
How Dapagliflozin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dapagliflozin interactionDapagliflozin Propanediol, MetforminXigduo XR
How Dapagliflozin Propanediol, Metformin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dapagliflozin Propanediol, Metformin interactionDapagliflozin Propanediol, Saxagliptin HydrochlorideQtern
How Dapagliflozin Propanediol, Saxagliptin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dapagliflozin Propanediol, Saxagliptin Hydrochloride interactionDapagliflozin, Metformin Hydrochloride, Saxagliptin HydrochlorideQternmet XR
How Dapagliflozin, Metformin Hydrochloride, Saxagliptin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dapagliflozin, Metformin Hydrochloride, Saxagliptin Hydrochloride interactionDasiglucagon HydrochlorideZegalogue
How Dasiglucagon Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dasiglucagon Hydrochloride interactionDulaglutideTrulicity
How Dulaglutide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Dulaglutide interactionEmpagliflozinJardiance
How Empagliflozin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Empagliflozin interactionEmpagliflozin, Linagliptin, Metformin HydrochlorideTrijardy XR
How Empagliflozin, Linagliptin, Metformin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Empagliflozin, Linagliptin, Metformin Hydrochloride interactionEmpagliflozin, MetforminSynjardy
How Empagliflozin, Metformin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Empagliflozin, Metformin interactionEmpagliflozin, Metformin HydrochlorideSynjardy XR
How Empagliflozin, Metformin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Empagliflozin, Metformin Hydrochloride interactionErtugliflozinSteglatro
How Ertugliflozin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Ertugliflozin interactionErtugliflozin, Metformin HydrochlorideSegluromet
How Ertugliflozin, Metformin Hydrochloride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Ertugliflozin, Metformin Hydrochloride interactionExenatideBydureon, Byetta
How Exenatide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Exenatide interactionExenatide SyntheticBydureon BCISE
How Exenatide Synthetic interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Exenatide Synthetic interactionGliclazideDiamicron
How Gliclazide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Gliclazide interactionGlimepirideAmaryl
How Glimepiride interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Glimepiride interactionGlipizideGlucotrol, Glucotrol XL
How Glipizide interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Glipizide interactionGlipizide, MetforminMetaglip
How Glipizide, Metformin interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Glipizide, Metformin interactionGlucagonBaqsimi, Glucagon
How Glucagon interacts with MyGLP-1 — through 1 ingredient. Tap an ingredient for the detail:
ChromiumAntidiabetes Drugs Moderate
Interaction Summary
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Read the full Chromium + Glucagon interactionEach ingredient & the kinds of drugs it affects
For each ingredient in MyGLP-1 with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.
Chromium
Antidiabetes Drugs
Theoretically, chromium may have additive effects with antidiabetic agents and increase the risk of hypoglycemia.
Some research shows that taking chromium might lower blood glucose levels, especially in patients with poorly controlled type 2 diabetes.
Insulin
Theoretically, concomitant use of chromium and insulin might increase the risk of hypoglycemia.
In clinical research, chromium has been shown to increase insulin sensitivity,
Levothyroxine (Synthroid, Others)
Chromium might bind levothyroxine in the intestinal tract and decrease levothyroxine absorption.
Clinical research in healthy volunteers shows that taking chromium picolinate 1000 mcg with levothyroxine 1 mg decreases serum levels of levothyroxine by 17% when compared to taking levothyroxine alone. Advise patients to take levothyroxine at least 30 minutes before or 3-4 hours after taking chromium.
Aspirin
Theoretically, aspirin might increase chromium absorption.
Animal research suggests that aspirin may increase chromium absorption and chromium levels in the blood.
Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
NSAIDs might increase chromium levels in the body.
Drugs that are prostaglandin inhibitors, such as NSAIDs, seem to increase chromium absorption and retention.
Brand information
Manufacturer and brand details for MyGLP-1, from the product label.
MyGLP-1 by Purity Products: Common Questions
Does MyGLP-1 by Purity Products interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
Can I take this if I'm on metformin or another diabetes pill?
Will it interfere with my thyroid medication (levothyroxine)?
Is chromium safe long-term?
What are the most common side effects?
Is it okay to take this while pregnant?
What do eriocitrin and slendacor do?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if MyGLP-1 is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind MyGLP-1’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Sources & How We Checked
MyGLP-1's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 53 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Chromium 53 references
- Cerulli J, Grabe DW, Gauthier I, et al. Chromium picolinate toxicity. Ann Pharmacother 1998;32:428-31. PubMed
- Urberg M, Zemel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism 1987;36:896-9. PubMed
- Mohamedshah FY, Moser-Veillon PB, Yamini S, et al. Distribution of a stable isotope of chromium (53Cr) in serum, urine, and breast milk in lactating women. Am J Clin Nutr 1998;67:1250-5. PubMed
- Wasser WG, Feldman NS, D'Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate. [letter]. Ann Intern Med 1997;126:410. PubMed
- Mertz W. Interaction of chromium with insulin: a progress report. Nutr Rev 1998;56:174-7. PubMed
- Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998;17:548-55. PubMed
- McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psych 1999;60:237-40. PubMed
- Fowler JF Jr. Systemic contact dermatitis caused by oral chromium picolinate. Cutis 2000;65:116. DOI
- Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995;35:273-80.
- Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
- Rabinovitz H, Friedensohn A, Leibovitz A, et al. Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004;74:178-82. PubMed
- Lanca S, Alves A, Vieira AI, et al. Chromium-induced toxic hepatitis. Eur J Intern Med 2002;13:518-20. PubMed
- Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy 2001;21:647-51.. PubMed
- Davidson JR, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003;53:261-4.. PubMed
- Food Standards Agency. Medicines and Healthcare products Regulatory Agency (MHRA). Expert Group on Vitamins and Minerals. Available at: http://cot.food.gov.uk/sites/default/files/vitmin2003.pdf.
- Mouser JF, Hak EB, Helms RA, et al. Chromium and zinc concentrations in pediatric patients receiving long-term parenteral nutrition. Am J Health Syst Pharm 1999;56:1950-6. PubMed
- Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med 2005;142:477-8. PubMed
- Wani S, Weskamp C, Marple J, Spry L. Acute tubular necrosis associated with chromium picolinate-containing dietary supplement. Ann Pharmacother 2006;40:563-6. PubMed
- Kleefstra N, Houweling ST, Jansman FG, et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006;29: PubMed
- Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826-32. PubMed
- Singer GM, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther 2006;8:636-43. PubMed
- John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. Thyroid 2007;17:763-5. PubMed
- Yazaki Y, Faridi Z, Ma Y, et al. A pilot study of chromium picolinate for weight loss. J Altern Complement Med 2010;16:291-9. PubMed
- Davis ML, Seaborn CD, and Stoecker BJ. Effects of over-the-counter drugs on chromium retention and urinary excretion in rats. Nutrition Research 1995;15(2):201-210.
- Young P, Turiansky G, Bonner M, and et al. Acute generalized exanthematous pustulosis induced by chromium picolinate. J.Am Acad.Dermatol. 1999;41(5 Pt 2):820-823. PubMed
- Gibb, H. J., Lees, P. S., Pinsky, P. F., and Rooney, B. C. Lung cancer among workers in chromium chemical production. Am J Ind.Med 2000;38(2):115-126. DOI
- Gibb, H. J., Lees, P. S., Pinsky, P. F., and Rooney, B. C. Clinical findings of irritation among chromium chemical production workers. Am J Ind.Med 2000;38(2):127-131. PubMed
- Pittler, M. H. and Ernst, E. Dietary supplements for body-weight reduction: a systematic review. Am.J.Clin Nutr. 2004;79(4):529-536. PubMed
- Pei, D., Hsieh, C. H., Hung, Y. J., Li, J. C., Lee, C. H., and Kuo, S. W. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism 2 PubMed
- Hisatomi, K., Ishii, H., Hashiguchi, K., Seki, M., Ide, M., Sugiyama, K., Ishimoto, H., Nakayama, S., Mukae, H., and Kohno, S. Interstitial pneumonia caused by inhalation of fumes of nickel and chrome. Respirology. 2006;11(6):814-817. PubMed
- Kleefstra, N., Houweling, S. T., Bakker, S. J., Verhoeven, S., Gans, R. O., Meyboom-de Jong, B., and Bilo, H. J. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled tri DOI
- Parsons, A., Ingram, J., Inglis, J., Aveyard, P., Johnstone, E., Brown, K., Franklin, M., and Bermudez, I. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to pr
- Bagdon RE and Hazen RE. Skin permeation and cutaneous hypersensitivity as a basis for making risk assessments of chromium as a soil contaminant. Environ.Health Perspect. 1991;92:111-119. PubMed
- Bharmal, S. V., Moyes, V., Ahmed, S., and Grossman, A. Hypoglycaemia: possible mediation by chromium salt medication. Hormones.(Athens.) 2010;9(2):181-183. PubMed
- Krol, E., Krejpcio, Z., Byks, H., Bogdanski, P., and Pupek-Musialik, D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol.Trace Elem.Res. 2011;143(2):726-737.
- Unisa, S., Jagannath, P., Dhir, V., Khandelwal, C., Sarangi, L., and Roy, T. K. Population-based study to estimate prevalence and determine risk factors of gallbladder diseases in the rural Gangetic basin of North India. HPB (Oxford) 2011;13(2):117-125. PubMed
- Noda, S., Asano, Y., and Sato, S. Lichen planus in a patient with long-term exposure to chrome. Eur.J.Dermatol. 2011;21(3):417-418. PubMed
- Xiang, J., Sun, Z., and Huan, J. N. Intensive chromic acid burns and acute chromium poisoning with acute renal failure. Chin Med.J.(Engl.) 7-5-2011;124(13):2071-2073.
- Chhabra, D., Oda, K., Jagannath, P., Utsunomiya, H., Takekoshi, S., and Nimura, Y. Chronic heavy metal exposure and gallbladder cancer risk in India, a comparative study with Japan. Asian Pac.J.Cancer Prev. 2012;13(1):187-190. PubMed
- Huszonek, J. Over-the-counter chromium picolinate. Am J Psychiatry 1993;150(10):1560-1561. PubMed
- Bunner S and McGinnis R. Chromium-induced hypoglycemia. Psychosomatics 1998;39(3):298-299. PubMed
- Martin, W. R. and Fuller, R. E. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy 1998;18(4):860-862. DOI
- Proctor, D. M., Fredrick, M. M., Scott, P. K., Paustenbach, D. J., and Finley, B. L. The prevalence of chromium allergy in the United States and its implications for setting soil cleanup: a cost-effectiveness case study. Regul.Toxicol Pharmacol 1998;28(1 PubMed
- De Marchi S, Cecchin E, De Marchi SU. Systemic allergic dermatitis resulting from oral administration of chromium with a food supplement. Contact Dermatitis 2014;70(2):123-5. PubMed
- Hedberg YS, Gumulka M, Lind ML, Matura M, Lidén C. Severe occupational chromium allergy despite cement legislation. Contact Dermatitis. 2014;70(5):321-3. PubMed
- Thyssen JP, Jellesen MS, Møller P, Menné T, Johansen JD. Allergic chromium dermatitis from wearing 'chromium-free' footwear. Contact Dermatitis 2014;70(3):185-7. PubMed
- Liu Y, Cotillard A, Vatier C, et al. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One.
- Jamilian M, Asemi Z. Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Nutr Metab. 2015;67(1):42-8. PubMed
- Guimarães MM, Carvalho AC, Silva MS. Effect of chromium supplementation on the glucose homeostasis and anthropometry of type 2 diabetic patients: Double blind, randomized clinical trial: Chromium, glucose homeostasis and anthropometry. J Trace Elem Med Bi PubMed
- Paiva AN, Lima JG, Medeiros AC, et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol. 2015;32:66-72. PubMed
- Yin RV, Phung OJ. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J. 2015;14:14. PubMed
- Jamilian M, Zadeh Modarres S, Amiri Siavashani M, et al. The influences of chromium supplementation on glycemic control, markers of cardio-metabolic risk, and oxidative stress in infertile polycystic ovary syndrome women candidate for in vitro fertilizati
- Alinaghi F, Thyssen JP, Zachariae C, Johansen JD. No immediate effect of regulatory reduction of chromium in leather among adult patients with chromium allergy. Contact Dermatitis 2021;85(5):514-522. PubMed
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC